Evidence map›Paper›PMID 33964183›Full record

Trial reportTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2021

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.

Hidetoshi Kanai, Masaomi Nangaku, Reiko Nagai, Nobuhiko Okuda, Kyo Kurata, Takashi Nagakubo, Yukihiro Endo, Alexander Cobitz

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  4. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2021
    Trial
  5. Daprodustat.Hospital pharmacy · 2023
    Review
  6. Review
  7. Review
  8. Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Hidetoshi KanaiDepartment of Nephrology, Kokura Memorial Hospital, Fukuoka, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan.
Reiko NagaiMedicines Development, GlaxoSmithKline, Tokyo, Japan.
Nobuhiko OkudaMedicines Development, GlaxoSmithKline, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6438-9906
Kyo KurataClinical Development, GlaxoSmithKline, Tokyo, Japan.
Takashi NagakuboDepartment of Biostatistics, GlaxoSmithKline, Tokyo, Japan.
Yukihiro EndoMedicines Development, GlaxoSmithKline, Tokyo, Japan.
Alexander CobitzClinical Sciences, GlaxoSmithKline, King of Prussia, Pennsylvania, USA.
GlaxoSmithKline (Japan) · JPGlaxoSmithKline (United Kingdom) · GBKokura Memorial Hospital · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dialysis patients with anemia over 52 weeks. Subjects received daprodustat 4 mg orally once daily for 4 weeks and the dose was subsequently adjusted every 4 weeks. Mean baseline hemoglobin was 10.9 g/dL (95% CI 10.59, 11.12). Mean hemoglobin reached the target range (11.0-13.0 g/dL) at week 12 and was maintained until week 52. Mean hemoglobin during weeks 40-52 was 12.1 g/dL (95% CI 12.0, 12.2). The most frequent adverse events included nasopharyngitis (29%), catheter-site infection (18%), peritonitis (16%), diarrhea (14%), and nausea (11%). No deaths were reported. Once-daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in Japanese peritoneal dialysis participants.

Indexed as

AnemiaBarbituratesCohort StudiesFemaleGlycineHumansJapanMaleMiddle AgedPeritoneal DialysisRenal Insufficiency, ChronicTreatment OutcomeBarbituratesGlycineGSK1278863anemiahypoxiaJapaneseperitoneal dialysis

Identifiers

PMID33964183
PMCPMC9290017
OpenAlexW3160185326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.